|
|
|
|
fact
sheet
GSTM1, GSTT1,
and the Risk of Squamous Cell Carcinoma of the Head and Neck
Stacy A. Geisler &
Andrew F. Olshan
print version
HuGE review
Published
August 9th, 2001
|
|
|
Gene |
|
GSTM1:
Polymorphism of this gene results in either production of an |
|
|
enzyme
known to play a role in Phase II detoxification of polycyclic aromatic
hydrocarbons found in tobacco smoke or no production of enzyme
(deletion polymorphism). This gene has been mapped to |
|
|
|
chromosome
1p13.3.
GSTT1:
Polymorphism of this gene results either in production of an enzyme known
to activate ethylene oxide, epoxybutanes, halomethanes, and methyle
bromide or no production of enzyme (deletion polymorphism). It is also
involved in Phase II detoxification of polyaromatic hydrocarbons (PAHs)
found in tobacco smoke (considered as a minor pathway). This gene has been
mapped to chromosome 22q11.2.
|
Prevalence of
Gene Variants |
|
GSTM1: In
the United States, case-control studies have reported the deletion
genotype varying from 23%-41% for those of African descent; 32%-53% for
those of Asian descent, 40%-53% for those of Hispanic descent, and 35%-62%
for those of European descent. Several population studies have reported
the deletion polymorphism among U.S. Caucasians as ranging from 48%-57%.
Other countries have reported varying frequencies of the deletion
polymorphism. South American case-control (nonpopulation-based) studies
have reported frequencies of 21% for Chileans and 55% for Caucasian
Brazilians, 33% for black Brazilians, and 20% for Amazonian Brazilians.
Among the French, 46% have been reported to carry the deletion genotype. A
large cross-sectional study conducted among Italians reported a frequency
of 53%; two studies conducted in Hungary and the Slovak Republic measured
frequencies of 44% and 50%, respectively. A population-based study
conducted in Finland found a prevalence of 40% for the GSTM1
deletion genotype. Groups such as Pacific Islanders and Malasians have a
reported frequency of 62%-100%. Other Asian populations have high-reported
frequencies of the deletion genotype ranging from 48%-50% for Japanese and
35%-63% for Chinese. A population-based study conducted among Chinese
reported a frequency of 51% for the GSTM1 deletion genotype. Two Korean
case-control studies found frequencies of 53% and 56% for the GSTM1
deletion genotype (1)
GSTT1:
Studies of GSTT1 demonstrate that in the United States, the
deletion polymorphism of GSTT1 is less common than the GSTM1
deletion polymorphism. Among those of European ancestry, 15%-31% have no
functional GSTT1 enzyme. African descendents have frequencies
ranging from 22%-29% while those of Hispanic origin carry GSTT1
deletions of 10%-12%. European studies have reported that the GSTT1
deletion genotype was present among 21% of Italians and 28% of Slovakians.
One South American study found that 19% of both Caucasian and black
Brazilians had the deletion genotype compared to 11% of Amazonian
Brazilians. Asians have the highest reported GSTT1 deletion
genotype. One study reported 58% of Chinese and 38% of Malaysians have the
GSTT1 null genotype; two case-control studies measured 42% and 46%
among Koreans. However, a recent population-based study conducted among
Chinese found a prevalence of 46% for the GSTT1 deletion genotype
among their study subjects (1)
|
Disease
Burden |
|
Worldwide, squamous
cell carcinoma of the head and neck (SCCHN) represents the third most
common cancer among men and the fourth most common among women. Tobacco
smoking remains the most important risk factor for SCCHN, with 90% of oral
cancers and 80% of larynx cancers attributed to this habit. Given the high
prevalence of the GSTM1 and GSTT1 deletion polymorphisms,
the population-attributable risk of disease is extremely high for those
who have the deletion genotype and who engage in tobacco smoking.
|
Interactions |
|
Twenty-four
studies have been published evaluating GSTM1, GSTT1, and the
risk of SCCHN. The main effect of the gene has been inconsistent, with
most studies reporting weak to moderate results. Modest evidence of
interaction has been shown with imprecise estimates of effect for risk of
SCCHN and GSTM1 null genotype among studies that have measured dose
and duration of tobacco exposure (2-4). For example, after adjustment for
age and gender, Sato et al. calculated odds ratios (OR) of 3.1 (1.6, 5.9),
3.9 (1.6, 9.1), and 16.2 (4.3, 61.0) for risk of oral cancer for those
with the GSTM1 deletion genotype and increasing lifetime cigarette dose
(4)
Among those studies
that have evaluated gene-environment interaction for the GSTT1
deletion genotype, Olshan et al. reported a suggestive interaction with
smoking. For those with the GSTT1 deletion genotype and who had
never smoked (never smokers), the risk of SCCHN was 2.7 (0.5, 12.9)
compared to never smokers without the GSTT1 deletion genotype.
Less-than-one-pack-per-day smokers had an OR of 3.7 (0.7, 19.4) while
one-pack-per-day-or-greater smokers had an OR of 7.0 (2.2, 22.0) compared
to never smokers without the GSTT1 deletion genotype (3).
|
|
|
|
Laboratory
Tests
|
|
Individuals with
homozygous deletions of either the GSTM1 locus or the GSTT1
locus have no enzymatic functional activity of the respective enzyme. This
has been confirmed by phenotype assays that have demonstrated 94% or
greater concordance between phenotype and genotype. Genotyping
methods used in the studies reviewed were consistent with the standard
techniques employed for PCR, PCR-restriction fragment length
polymorphisms, and multiplex PCR. Internal control primers were
stated for all studies.
|
Population
Testing |
|
No population
testing has been conducted to date, and none are indicated.
|
References |
|
1.
Geisler S, Olshan A. GSTM1,
GSTT1 and risk of head and neck cancer: a mini-HuGE review. American
Journal of Epidemiology 2001;154:95-105.
2.
Park J, Muscat J, Kaur T, Schantz S, Stern J, Richie J, et al. Comparison
of GSTM polymorphisms and risk for oral cancer between African Americans and
Caucasians. Pharmacogenetics 2000;10:123-31.
3.
Olshan A, Weissler M, Watson M, Bell D. GSTM1, GSTT1, GSTP1, CYP1A1, and
NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer
Epidemiol Biomarkers Prev 2000;9:185-91.
4.
Sato M, Sato T, Izumo T, Amagasa T. Genetic Polymorphism of drug-metabolizing enzymes and susceptibility to oral
cancer. Carcinogenesis 1999,20:1927-31.
|
|
Web sites |
|
National
Cancer Institute
GENE
CARD for GSTM1
Rebhan, M., Chalifa-Caspi, V., Prilusky, J., Lancet, D.
GeneCards: encyclopedia for genes, proteins and diseases.
Weizmann Institute of Science, Bioinformatics Unit & Genome Center (Rehovot,
Israel), 1997. GeneCard for GSTM1, Last Update: 8 Jun 2001
GENE
CARD for GSTT1
Rebhan, M., Chalifa-Caspi, V., Prilusky, J., Lancet, D.
GeneCards: encyclopedia for genes, proteins and diseases.
Weizmann Institute of Science, Bioinformatics Unit & Genome Center (Rehovot,
Israel), 1997. GeneCard for GSTT1, Last Update: 8 Jun 2001
|
|
|
|
|
|